ARVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ARVN is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a major positive catalyst from FDA approval of Veppanu, and analysts have turned more constructive with rising price targets, but the technical setup is still mixed, the latest quarter shows a sharp revenue decline, and the options market is sending a conflicted but generally speculative signal rather than a clean bullish confirmation. Because the user wants a direct answer and is not waiting for an ideal entry, my view is to hold off on buying now and wait for better post-catalyst confirmation.
ARVN closed at 10.18, essentially flat versus the prior close of 10.19, with a small regular-session decline and mild after-hours softness. RSI_6 at 40.4 is neutral-to-weak, MACD histogram is slightly positive but contracting, and moving averages are converging, which suggests a sideways-to-indecisive trend rather than a strong breakout. Key levels matter: pivot 10.477 is just above the current price, resistance sits at 11.115 and 11.509, while support is 9.839 and 9.445. The modeled near-term trend suggests possible short-term weakness next day/week, with better improvement over the next month, so the technical picture does not yet support an aggressive immediate entry.
The biggest positive catalyst is FDA approval of Veppanu, which materially de-risks the platform and creates a real commercial opportunity. News also indicates a planned commercialization deal, which could improve revenue visibility. Analyst sentiment has improved meaningfully, with multiple target increases and Buy/Overweight ratings. The company also has cash runway into the second half of 2028 according to Piper Sandler, supporting execution on the pipeline. The upcoming QMAR 2026 earnings on 2026-05-12 could provide another catalyst if management shows commercial progress.
The stock is also trading below its pivot level, and the short-term technical setup is not yet confirmed. Hedge funds and insiders are both neutral, so there is no strong ownership-based accumulation signal. The near-term pattern analysis also points to modest downside over the next day and week.
In Q4 2025, Arvinas reported sharply lower revenue of $9.5M, down 83.95% year over year, which is the main weakness in the latest results. Losses improved somewhat, with net income at -$67.4M and EPS at -1.04, both better than the prior year on a percentage basis, but the company is still loss-making. Gross margin was reported at 100%, which is typical for a development-stage biotech with limited revenue base. Overall, the latest quarter shows cost and loss improvement, but growth trends are still weak until Veppanu commercialization starts contributing.
Analyst sentiment has clearly improved over the past few months. Citi raised its target from $15 to $18, then to $21, and most recently to $24, while maintaining a Buy rating, citing FDA approval as a major de-risking event. Piper Sandler is Overweight with a $20 target, Evercore ISI is Outperform with a $19 target, and Wedbush remains Neutral with an $11 target, showing a split but improving Wall Street view. Overall, pros see a de-risked platform, strong pipeline optionality, and a pivotal 2026, while the cautious camp is waiting for more clinical and commercial proof.
